Skip to main content
. Author manuscript; available in PMC: 2016 Sep 13.
Published in final edited form as: J Urol. 2010 Nov 12;185(1):104–110. doi: 10.1016/j.juro.2010.08.088

Figure 2.

Figure 2

ROC curves for all markers in all 474 subjects (A) and in 223 subjects with PSA in 2 to 10 ng/ml range (B). Asterisk indicates markers were lower in cancer group vs noncancer group. Therefore, sensitivity was defined as proportion of cancer cases with biomarker value equal to or less than cut point and specificity as proportion of controls with biomarker value exceeding cut point.